secwatch.observer — SEC 8-K summary
======================================

Issuer:     Opus Genetics, Inc. (IRD)
CIK:        0001228627
Form:       8-K
Filed at:   2022-11-07T23:59:59+00:00
Accession:  0001140361-22-040303
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ocuphire licenses Nyxol to FamyGen/Viatris for $35M upfront plus milestones and royalties
--------------------------------------------------------------------------------

- Ocuphire receives $35M upfront; FamyGen funds Nyxol development through FDA approvals.
- Up to $130M in milestones; first $10M on FDA approval for mydriasis reversal expected in 2023.
- Tiered double-digit royalties on worldwide net sales through 2040.
- Viatris to commercialize Nyxol globally; Ocuphire retains rights outside licensed territory.
- Cash position extended into 2025, supporting presbyopia/NVD trials and APX3330 retina program.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1228627/000114036122040303/0001140361-22-040303-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1228627/000114036122040303/brhc10043812_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-22-040303

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer